4//SEC Filing
O'Neill Vincent 4
Accession 0001104659-24-100747
CIK 0001720893other
Filed
Sep 16, 8:00 PM ET
Accepted
Sep 17, 7:19 PM ET
Size
9.1 KB
Accession
0001104659-24-100747
Insider Transaction Report
Form 4
O'Neill Vincent
Other
Transactions
- Exercise/Conversion
Common Stock
2024-09-14+521→ 4,045 total - Sale
Common Stock
2024-09-16$0.69/sh−138$95→ 3,907 total - Exercise/Conversion
Restricted Stock Units
2024-09-14−521→ 3,127 total→ Common Stock (521 underlying)
Footnotes (3)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.
- [F3]On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Documents
Issuer
BioXcel Therapeutics, Inc.
CIK 0001720893
Entity typeother
Related Parties
1- filerCIK 0001672718
Filing Metadata
- Form type
- 4
- Filed
- Sep 16, 8:00 PM ET
- Accepted
- Sep 17, 7:19 PM ET
- Size
- 9.1 KB